Abstract

Recently, a novel type 1 diabetes association locus was identified at human chromosome 6p31.3, and transcription factor 19 (TCF19) is a likely causal gene. Little is known about Tcf19, and we now show that it plays a role in both proliferation and apoptosis in insulinoma cells. Tcf19 is expressed in mouse and human islets, with increasing mRNA expression in nondiabetic obesity. The expression of Tcf19 is correlated with β-cell mass expansion, suggesting that it may be a transcriptional regulator of β-cell mass. Increasing proliferation and decreasing apoptotic cell death are two strategies to increase pancreatic β-cell mass and prevent or delay diabetes. siRNA-mediated knockdown of Tcf19 in the INS-1 insulinoma cell line, a β-cell model, results in a decrease in proliferation and an increase in apoptosis. There was a significant reduction in the expression of numerous cell cycle genes from the late G1 phase through the M phase, and cells were arrested at the G1/S checkpoint. We also observed increased apoptosis and susceptibility to endoplasmic reticulum (ER) stress after Tcf19 knockdown. There was a reduction in expression of genes important for the maintenance of ER homeostasis (Bip, p58IPK, Edem1, and calreticulin) and an increase in proapoptotic genes (Bim, Bid, Nix, Gadd34, and Pdia2). Therefore, Tcf19 is necessary for both proliferation and survival and is a novel regulator of these pathways.

Highlights

  • BOTH TYPE 1 DIABETES MELLITUS (T1DM) and type 2 diabetes mellitus (T2DM) are diseases of insufficient functional ␤-cell mass

  • We find that transcription factor 19 (Tcf19) expression is highly correlated with proliferation in the islet

  • We further show that Tcf19 is necessary for growth and survival in INS-1 cells through transcriptional regulation of key cell cycle genes and genes involved in apoptotic pathways

Read more

Summary

Introduction

BOTH TYPE 1 DIABETES MELLITUS (T1DM) and type 2 diabetes mellitus (T2DM) are diseases of insufficient functional ␤-cell mass. Autopsy studies have shown that individuals with T2DM have reduced ␤-cell mass due to decreased proliferation and increased apoptosis [5, 19]. ␤-Cell mass increases due to proliferation, hypertrophy, and neogenesis, whereas it decreases due to apoptosis and atrophy [1]. A smaller number of factors that can impact both ␤-cell proliferation and apoptosis have been identified [20]. A therapeutic intervention with the capacity to impact both proliferation and survival would result in an additive benefit to ␤-cell mass. We initially identified transcription factor 19 (Tcf19) in a microarray of islet gene expression in mouse models of obesity and diabetes. Within this model, obesity is induced in both the.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.